Affymax Inc (AFFY)

In the eyes of most market participants, hedge funds are perceived as slow, outdated investment vehicles of the past.

Short-sellers certainly huffed and puffed with all of their might in May, but it wasn't meant to be: The tech-heavy NASDAQ Composite (INDEXNASDAQ:.IXIC) rose another 3.8%, extending its year-to-date gains...

In today’s marketplace, there are many metrics investors can use to watch Mr. Market. A couple of the most under-the-radar are hedge fund and insider trading interest.

Biotechs offer the possibility of monster returns. Overnight doubles aren't out of the question.

The drug development field is a potentially lucrative, although always dangerous area for small companies and their investors to participate in.

You won't often hear me say this, but it's a pretty quiet week on the health-care front.

With the SPDR S&P Biotech Index up 23% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.

The Dow Jones Industrial Average finished strong last week, and eked out a closing price just above the 14,000 mark.

At the end of last year, I proclaimed Omontys -- an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells -- as one of my 10 drugs approved by the Food and Drug Administration...